Company Intelligence Profile
CELAGENEX RESEARCH (INDIA) PRIVATE LIMITED
Celagenex is a biotech/specialty-pharma group developing therapies for chronic lifestyle diseases (diabetes, cardiac conditions, stroke, Alzheimer's, neuropathies) using endogenous metabolites and bioavailability-enhancer technology; holds ~13 patents issued/filed globally.
AI-generated summary from public filings and may contain errors. Verify against the detailed sections below.
Company Identity
Confirmed| Registered name | CELAGENEX RESEARCH (INDIA) PRIVATE LIMITED |
|---|---|
| CIN | U36997MH2019PTC331430 |
| PAN | AAICC4124A (confirmed — Tofler + GSTIN cross-check, PAN embedded in GSTIN 27AAICC4124A1Z7) |
| Status | Active |
| Listing | Unlisted (private limited company) |
| Incorporated | 09 October 2019 |
| ROC | Registrar of Companies, Mumbai (Maharashtra) |
| Sector (NIC) | CIN industry code 36997 (generic "other manufacturing n.e.c." MCA classification). Actual registered activity per registry filings: management consultancy activities and research/experimental development in medical sciences (pharma/biotech). Business-description sources classify it under pharmaceutical retail & distribution. |
| Registered address | 6th Floor, Bellona Building, Behind The Walk, Hiranandani Estate, Kolshet Village, Chitalsar Manpada, Thane (W), Maharashtra – 400607 (confirmed, 2 sources) |
| Authorized capital | INR 5.00 lakh (confirmed, 2 sources) |
| Paid-up capital | INR 1.77–1.80 lakh (confirmed, 2 sources; minor rounding variance) |
Business Overview
Partial / conflicting- Celagenex is a biotech/specialty-pharma group developing therapies for chronic lifestyle diseases (diabetes, cardiac conditions, stroke, Alzheimer's, neuropathies) using endogenous metabolites and bioavailability-enhancer technology
- holds ~13 patents issued/filed globally
- Celagenex Research (India) Pvt Ltd is the Indian entity — MCA filings classify it under management-consultancy / medical-sciences R&D, while commercial trackers describe its on-ground activity as pharmaceutical retail and distribution (i.e., it appears to run the India commercialisation/R&D arm of the Celagenex brand)
- Company is DPIIT-recognised as a startup
- Source: celagenex.com (official site, describing the "Celagenex" technology platform and business, HQ address shown as San Ramon, California), thecompanycheck.com (India registry + business description)
Directors
Confirmed| Name | DIN | Role | Appointed |
|---|---|---|---|
| Rajaram (Shriram) Samant | 02777466 | director since 25 Mar 2020; also the founder of the US "Celagenex" entity per Tracxn San Ramon, CA, suggesting he is the common founder linking the India and US operations. | - |
| Shoyeb Abdul Gafoor Mandlekar | 08581970 | - | - |
| Dilip Gopal Nevrekar | 09728733 | director since 01 Sep 2022. Last AGM: 18 September 2025 thecompanycheck / 06 August 2024 Tofler; dates conflict across sources, not reconciled. | - |
GST Registrations
Partial / conflicting| GSTIN | State | PAN | Status |
|---|---|---|---|
| 27AAICC4124A1Z7 | Maharashtra | AAICC4124A (confirmed — Tofler + GSTIN cross-check, PAN embedded in GSTIN 27AAICC4124A1Z7) | Active |
| 24AAICC4124A1ZD | Gujarat | AAICC4124A (confirmed — Tofler + GSTIN cross-check, PAN embedded in GSTIN 27AAICC4124A1Z7) | - |
| 36AAICC4124A1Z8 | Telangana | AAICC4124A (confirmed — Tofler + GSTIN cross-check, PAN embedded in GSTIN 27AAICC4124A1Z7) | - |
Primary/home-state GSTIN: 27AAICC4124A1Z7 (Maharashtra) — confirmed by 2 sources (knowyourgst.com, mastersindia.co): Active, Regular taxpayer, registered 05 Dec 2019, principal place of business 6th Floor Bellona, Hiranandani Estate, Thane (W), Maharashtra 400607, legal name matches exactly. Additional registrations found via aggregator search (single-source, not yet cross-verified on individual GSTIN pages): 24AAICC4124A1ZD (Gujarat, reg. 01 Jul 2021) and 36AAICC4124A1Z8 (Telangana, reg. 17 Feb 2020); one snippet also referenced a Uttar Pradesh registration, unconfirmed. PAN across all: AAICC4124A. Total registrations: at least 3, possibly 4 — count not fully reconciled across sources.
Financials
Partial / conflictingFY2025 (year ended 31 Mar 2025), standalone, as reported by commercial trackers (not sourced from a filed annual report/PDF):
| Revenue | ~₹156.68 crore (thecompanycheck) / "₹150–200 cr" band with +52.91% YoY growth (Tofler) — two sources agree directionally and roughly in magnitude (~53% YoY growth); treated as confirmed-in-range |
|---|---|
| EBITDA / PAT / Net profit | not obtained (paywalled on both trackers) |
| Net worth | Tofler reports a YoY change of "-238.4%" — a large negative swing (may indicate net worth turned negative or was sharply eroded); not corroborated by a second source, and absolute value not obtained. Flag as partial/unverified — needs a filed balance sheet to confirm |
| Borrowings | Tofler shows +34.8% YoY increase in borrowings; however both Tofler and thecompanycheck separately state "no registered charges" on company assets — so any increased borrowing appears unsecured/related-party/inter-company rather than charge-backed. Total assets: +26.12% YoY (Tofler) |
| Employees | 687 per EPFO data as of 06 Mar 2025 (thecompanycheck, single source) |
No standalone vs consolidated distinction was disclosed; company is small enough that consolidated accounts are unlikely to apply.
Charges/Loans
ConfirmedNo registered charges — confirmed by 2 independent sources (Tofler, thecompanycheck): "company has no registered charges" / "None registered." Note the tension with Tofler's own reported +34.8% YoY borrowings increase (see financials) — likely unsecured debt.
Legal (Indian Kanoon)
Partial / conflictingIndian Kanoon lists several proceedings involving the company (case titles/dates found via search aggregation, not verified against full judgment text):
- Celagenex Research India Pvt Ltd vs Pharmak & Anr — Delhi High Court (hearings/orders dated 30 May 2025 and 22 Dec 2025) — appears to be a commercial/IP dispute where Celagenex is plaintiff.
- Nugenesys Pharmaceuticals Pvt. Ltd. vs Celagenex Research (India) Pvt. Ltd. — Delhi High Court (orders dated 13 & 16 Jul 2026) — Celagenex as defendant in a separate commercial dispute.
- Celagenex Research India Private vs Deputy Controller of Patents and Designs — Bombay High Court, multiple orders (20 Aug 2025, 17 Jan 2026, 29 Jan 2026, 26 Feb 2026, 23 Apr 2026) — appears to be a recurring patent-prosecution/appeal matter, consistent with the company's stated large patent portfolio.
Case list is from search-snippet aggregation only; full case text and outcomes were not read and should be verified directly on indiankanoon.org before publishing specifics.
Competitors
Partial / conflictingIndia-focused specialty/metabolic-disease and licensed-technology pharma peers (rough scale tags, revenue-band estimates, not verified against each company's own filings): 1. Eris Lifesciences — metabolic disease (diabetes/cardiac) focused, listed, much larger (~₹1,800+ cr revenue). 2. USV Pvt Ltd — diabetes/cardiovascular specialty pharma, large private company (~₹3,000+ cr revenue). 3. Themis Medicare — specialty/licensed-technology pharma, listed, small-mid cap. 4. Marksans Pharma — listed, formulations manufacturer, mid-cap. 5. Curatio Healthcare — dermatology/specialty licensed-brand model, mid-size private. These are directional peer suggestions based on sector/business-model similarity (metabolic disease focus, licensing-driven specialty pharma), not a verified competitor set from a primary source.
Frequently Asked Questions
What does CELAGENEX RESEARCH (INDIA) PRIVATE LIMITED do?
What is the CIN of CELAGENEX RESEARCH (INDIA) PRIVATE LIMITED?
Where is CELAGENEX RESEARCH (INDIA) PRIVATE LIMITED registered?
Looking for business funding?
Recur Club is India's largest AI-native debt platform - working capital, term loans and structured debt from 150+ lending partners, without diluting equity.